[{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Orkla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Orkla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orkla \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Orkla \/ Undisclosed"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Orange Grove Bio"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Research Bridge Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Research Bridge Partners","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Research Bridge Partners"}]

Find Clinical Drug Pipeline Developments & Deals for DuoPlant Gel

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Under the agreement, Dr. Reddy’s divests certain non-core brands including Hydroheal, Gris ODT, Revilus, Revibra, Avarta, Salicylix (salicylic acid), Clearz, Acrofy and Aquaderm, in dermatology in India to Eris Lifesciences.

                          Product Name : Salicylix

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 16, 2023

                          Lead Product(s) : Salicylic Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Eris Pharmaceuticals

                          Deal Size : $33.2 million

                          Deal Type : Divestment

                          Dr Reddy Company Banner

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Salicylic acid helps soften, lift, and clear away flakes of skin on psoriasis plaques. It helps to control the symptoms of psoriasis and provides relief from itching, irritation and redness.

                          Product Name : DERMAdoctor

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 21, 2023

                          Lead Product(s) : Salicylic Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          February 23, 2021

                          Lead Product(s) : Salicylic Acid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Research Bridge Partners

                          Deal Size : $2.0 million

                          Deal Type : Financing

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Orkla Corn Plaster (Salicylic Acid) is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Callosities.

                          Product Name : Orkla Corn Plaster

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 23, 2020

                          Lead Product(s) : Salicylic Acid

                          Therapeutic Area : Podiatry

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          August 25, 2020

                          Lead Product(s) : Salicylic Acid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Orange Grove Bio

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          06

                          Grossman, Michael, D.P.M.

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Grossman, Michael, D.P.M.

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Salicylate is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Warts.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 23, 2012

                          Lead Product(s) : Salicylic Acid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Main Line Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank